Risk of hepatitis B reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with lung cancer receiving adjuvant chemotherapy
10.3760/cma.j.issn.1000-6680.2013.01.006
- VernacularTitle:HBsAg阴性或抗-HBc阳性者肺癌术后辅助化学治疗中乙型肝炎病毒的再激活
- Author:
Junyan YU
;
Xiaohong HU
;
Rong ZHANG
;
Xianli QIAO
;
Ningning ZHANG
;
Ping LIU
;
Lulu LI
;
Ranxin HUANG
;
Xiangyang TIAN
;
Zibai WEI
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Chemotherapy,adjuvant;
Hepatitis B;
Hepatitis B surface antigens;
Hepatitis 13 core antigens;
Hepatitis 13 antibodies;
Postoperative period
- From:
Chinese Journal of Infectious Diseases
2013;(1):24-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective To identify the rate of hepatitis B virus (HBV) reactivation and potential risk factors in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with lung cancer receiving adjuvant chemotherapy without concomitant antiviral prophylaxis.Methods The records of 3280 patients with lung cancer who received adjuvant chemotherapy were retrospectively reviewed from January 2003 to December 2011.Among these patients,367 hepatitis B surface antigen negative/hepatitis B core antibody positive patients were analyzed for the HBV reactivation in this study.The HBV serology marker and biochemical tests of the 367 patients were performed.The data were analyzed by chi square test.Results Among 367 hepatitis B surface antigen negative/hepatitis B core antibody positive patients with lung cancer,14 patients suffered HBV reactivation.Univariate analysis showed that age≥70 years(x2 =13.003,P=0.019),abnormal liver computed tomography findings (x2 =11.225,P =0.026) and the amount of corticost eroids≥ 150 mg(x2 =7.008,P =0.033)were associated with HBV reactivation.However,gender and adjuvant chemotherapy regimens were not related with HBV reactivation.Conclusion HBV reactivation occurs in a proportion of hepatitis B surface antigen negative/hepatitis B core antibody positive patients with lung cancer during adjuvant chemotherapy.
